Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

Publication Date: April 19, 2022

Key Points

Key Points

This guideline update provides evidence-based recommendations to optimally use currently available biomarkers in the population of women presenting with early-stage breast cancer with known estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) status.

Diagnosis

...gnosis...

...ER-positive, HER2-negative Breast Cancer...

...X (21-gene recurrence score)...

...ecommendation 1.1If a patient has node...

...dation 1.2In the group of patients...

...n 1.3In the group of patients in Recommendat...

...ndation 1.4If a patient is postmenop...

...ecommendation 1.5In the group of patients...

...1.6If a patient is premenopausal and has n...

...dation 1.7If a patient has node-pos...

...Print (70-gene signature)...

...1.8If a patient is older than 50 and has high...

...endation 1.9If a patient is 50 years of...

...ndation 1.10If a patient has low clinical risk...

...on 1.11If a patient has node-positiv...

...redict (12-gene risk score)

...ommendation 1.12If a patient is po...

...n 1.13If a patient is premenopausal and h...

...ecommendation 1.14If a patient has breast ca...

...osigna (PAM50...

...mendation 1.15If a patient is postmenopausal and h...

...mmendation 1.16If a patient is premenopausal,...

...ommendation 1.17If a patient is postmenopausal a...

...commendation 1.18If a patient has node-positive...

Mammostra...

...ufficient evidence to recommend us...

...st Cancer Index (BCI)...

...a patient has ER-positive, HER2-nega...

...s ER-positive, HER2-negative, node-positive breast...

...i67

...mendation 1.19If a patient is postmenop...

...commendation 1.20If a patient is p...

...1.21Despite the limitations associat...

...ohistochemistry 4 (IH...

Recommendation 1.22If a patient has n...

uPA and PA...

...ER-positive, HER2-negative (node-negative) br...

If a patient has HER2-positive breast cancer or...


...rine Therapy For ER Receptor-positiv...

...e DX, EndoPredict, Prosigna, Ki67,...

...1.23If a patient has node-negative...

...CI

Recommendation 1.24If a patient has node-negative...

...dation 1.25If a patient has node-po...

...inical Treatment Score post-5 Years...

...ndation 1.26If a patient is postmenopausal and...


...sitive Breast Cancer or TNBC...

...doPredict, MammaPrint, BCI, Prosigna, Ki6...

...ecommendation 1.27If a patient has HE...


Emerging Biomark...

...rating Lymphocytes (TILs)...

...1.28If a patient has node-negative o...

...1 TestingĀ ...

...endation 1.29If a patient has node-negative or no...

...irculating Tumor Cell...

...on 1.30If a patient has node-negative or node-posi...

...irculating Tumor DNA (...

...mendation 1.31If a patient has node-negative or n...


Table 1. Breast Cancer Biomarkers to Gu...


...gure 1. Algorithm on Biomarkers to Guide Deci...


...2. Classification of Patients Accord...


...ASCO believes that cancer clinical...